Printer Friendly

Evoke Pharma incurs higher net loss of USD3.0m in Q3 2016.

M2 PHARMA-November 10, 2016-Evoke Pharma incurs higher net loss of USD3.0m in Q3 2016

(C)2016 M2 COMMUNICATIONS

Pharmaceutical company Evoke Pharma (NasdaqCM:EVOK) stated on Wednesday that it recorded a net loss of USD3.0m (USD0.29 per share) for the third quarter ended 30 September 2016.

This is compared with a lower net loss of approximately USD2.7m (USD0.42) per share) for the three month period ended 30 September 2015.

Research and development (R&D) expenses of USD1.3m were recorded for the three months ended 30 September 2016, a decline from R&D of USD1.8m for the three months ended 30 September 2015.

As of 30 September 2016, the company's cash and cash equivalents were about USD10.4m and total assets were USD10.8m.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Financial report
Date:Nov 10, 2016
Words:141
Previous Article:Relevium Technologies appoints new Advisory Board members.
Next Article:MannKind resolves agreement with Sanofi for AFREZZA (insulin).

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters